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The amino acid sequence of amyloid precursor protein (APP)
is highly conserved, and age-related A aggregates have been
described in a variety of vertebrate animals, with the notable
exception of mice and rats. Three amino acid substitutions dis-
tinguish mouse and human A that might contribute to their
differing properties in vivo. To examine the amyloidogenic
potential of mouse A, we studied several lines of transgenic
mice overexpressing wild-type mouse amyloid precursor pro-
tein (moAPP) either alone or in conjunction with mutant PS1
(PS1dE9). Neither overexpression of moAPP alone nor co-ex-
pression with PS1dE9 caused mice to develop Alzheimer-type
amyloid pathology by 24 months of age. We further tested
whether mouse A could accelerate the deposition of human
A by crossing the moAPP transgenic mice to a bigenic line
expressing human APPswe with PS1dE9. The triple transgenic
animals (moAPP  APPswe/PS1dE9) produced 20% more A
but formed amyloid deposits no faster and to no greater extent
than APPswe/PS1dE9 siblings. Instead, the additional mouse
A increased the detergent solubility of accumulated amyloid
and exacerbated amyloid deposition in the vasculature. These
findings suggest that, althoughmouseAdoes not influence the
rate of amyloid formation, the incorporation of A peptides
with differing sequences alters the solubility and localization of
the resulting aggregates.
Although genetically engineered mice have become a com-
monly used tool for Alzheimer disease research, wild-type rats
and mice do not innately develop age-associated amyloid
pathology (1). Many other animals, including dogs, bears, and
primates, display amyloid lesions similar to those of Alzheimer
disease in humans (2–6). The lesions are formed by the aggre-
gation of a small peptide, A, common to all of these species.
The amyloid precursor protein (APP),3 from which A is
derived, is well conserved, and 96% of the amino acid
sequence is identical between mouse, rat, monkey, and human
(1, 7–9). The reason for rodents’ relative resistance to amyloid
pathology remains unknown, although several hypotheses have
been proposed, including the importance of amino acid
sequence differences in the peptide (10), the short lifespan of
rodents relative to other animals (11), and differences in proc-
essing ofmouseAPPby-siteAPP-cleaving enzyme 1 (BACE1)
(12).
Only 17 amino acid differences distinguish moAPP from its
human homolog; however, three of these differences are
locatedwithin theN-terminal domain of the A peptide (Fig. 1;
Arg-53Gly, Tyr-103 Phe, and His-133Arg). This region is
thought to be important for the specificity of interaction
between A peptides, whereas the hydrophobic C-terminal
sequence governs the rate of A aggregation (13–15). Despite
these three amino acid substitutions, in vitro studies using syn-
theticApeptides revealed nodifference in the ability of rodent
and human peptides to form congophilic filaments in aqueous
buffers (16, 17). Peptides from the two species can also co-
aggregate in solution to form mixed A fibers (17). The
sequence differences are not completely without consequence,
however. The replacement of His-13 for Arg in rodent A
disrupts a metal coordination site, which renders the rodent
peptide much less prone to zinc-induced aggregation in vitro
(18–20).
The amino acid sequence of A also affects interactions with
APP-processing enzymes (21). BACE1 is responsible for releas-
ing the N terminus of A from APP at either of two cleavage
sites within the peptide sequence: 1 or 11. When murine
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cessed to generate A starting predominantly at the1 site. In
contrast, murine BACE1 preferentially cleaves endogenous
APP at the11 site (12, 22–25). The effect of this truncation on
the aggregation of A is subject to debate: published reports
describe both enhanced and reduced aggregation (oligomeriza-
tion or sedimentation) in vitro of N-terminally truncated A
(26, 27).
Transgenic mice overexpressing human APP form amyloid
deposits composed primarily of human A. In addition, these
mice harbor low levels of mouse A beginning at both1 and
11. Pype et al. (28) show that the amount of mouse A
extracted from the brains of transgenicmice increased dramat-
ically with the formation of humanA deposits, suggesting that
the mouse peptide was co-depositing in the amyloid. However,
mouse peptide comprised only about 5% of the total A recov-
ered from the oldest animals tested. Moreover, Calhoun et al.
(29) have shown that removing mouse APP expression in
human APP transgenic mice had no impact on the extent or
location of amyloid formation, indicating that the mouse pep-
tide plays little or no role in the rate of amyloid formation in the
presence of high levels of human A.
To date, only one study has addressed the effects of elevating
murine A in vivo by overexpressing wild-type moAPP (30).
This study examined animals only 3.5–4 months of age and,
therefore, did not test whether overexpression of moAPP
would induce late onset amyloid formation. A complicating
factor in this initial study was the FVB background strain used
to generate the transgenic lines. Transgenic mice of this strain
are prone to premature death when human APP is expressed
via the hamster prion protein promoter (PrP) vector (30). We
have subsequently moved one of these original moAPP trans-
genic lines out of the FVBbackground by crossing onto a hybrid
C3H/HeJ  C57BL/6J strain for more than five generations.
This strategy eliminated the premature death of animals, allow-
ing us to examine the potential for amyloid formation in aged
moAPP transgenic mice. We report here that neither overex-
pression of moAPP alone, nor co-expression with the human
presenilin-1 exon-9 deletion variant (PS1dE9 (11, 31)), resulted
in amyloid composed only from mouse A. We further dem-
onstrate that mouse A does not accelerate the deposition of
human A in transgenic mice overexpressing both peptides,
but reveal that high levels of mouse peptide alter the solubility
of the resulting A aggregates and increase the prevalence of
vascular deposits. We further find that A11–40/42, predicted
to be the predominant form of A produced frommouse APP,
does not appear to be a major co-depositing peptide. These
findings provide insight into the potential role of specific A
sequences inmodulating the solubility and distribution of amy-
loid deposits in rodent models.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice—All transgenic mice used in
this study have been described and fully characterized in earlier
publications. All transgenes were expressed under control of
the mouse prion protein promoter (MoPrP.Xho), which drives
high protein expression in neurons and astrocytes of the central
nervous system (31, 32). Line S-9, expressing human PS1 har-
boring the FAD exon-9 deletion (PS1dE9), is described in Lee et
al. (33). Line 1874, expressing wild-type mouse APP (moAPPwt),
is described in Hsiao et al. (30). Line 85, co-expressing human
PS1dE9 and mouse/human (mo/hu) chimeric APP695
(humanized A domain) harboring the Swedish (K594M/
N595L) mutation, is described in Jankowsky et al. (11). Unlike
lines S-9 and 1874, line 85 was created by co-injecting two
transgenes, each driven by their own prion promoter element.
The two transgenes co-integrated and co-segregate as a single
locus (34). Lines 85 and S-9 have been deposited with Jackson
Laboratories (Bar Harbor,ME) for distribution (Stock numbers
004462 and 005866, respectively). After these experiments
were completed, line 1874 was lost through accidental mistyp-
ing of breeding stock.
Line 85 and line S-9 animals used in this study were main-
tained on a hybrid background by backcrossing to C3HeJ 
C57BL/6J F1 animals obtained from Jackson Laboratories. Line
1874 was backcrossed to C57BL/6J for two generations after it
was originally generated on the FVB background. After discov-
ering premature lethality in the offspring, the line was crossed
back to the hybrid C3HeJ  C57BL/6J F1 strain for two addi-
tional generations, which restored normal longevity to the line.
Offspring from the second C3/B6 backcross were used as
breeders to generate the cohorts described in this study.
Offspring were genotyped for the presence of the transgene
by PCRamplification of genomicDNAextracted from1-cm tail
clippings as described previously (34). Reactions contained
three primers, one antisense primer matching sequence within
the vector that is also present in mouse genomic PrP (5: GTG
GAT ACC CCC TCC CCC AGC CTA GAC C), one sense
primer specific for the transgene cDNA (PS1: 5: CAG GTG
GTG GAG CAA GAT G, huAPP: 5: CCG AGA TCT CTG
AAGTGAAGATGGATG, moAPP: 5: CCT TCAGGATTT
GAA GTC CGC), and a second sense primer specific for the
genomic PrP coding region, which has been removed from the
MoPrP vector (5: CCT CTT TGTGAC TATGTGGAC TGA
TGT CGG). All reactions give a 750-bp product from the
endogenous PrP gene as a control for DNA integrity and suc-
cessful amplification; transgene-positive samples have an addi-
tional band at 400 bp (huAPP), 350 bp (moAPP) or 1.3 kb (PS1).
Animals were housed in microisolator cages with free access
to food and water. All procedures involving animals were
approved by the JohnsHopkinsUniversity Institutional Animal
Care and Use Committee.
FIGURE 1.Mouse and humanA differ in primary sequence andN-termi-
nal processing. Three amino acid differences at residues 5, 10, and 13 distin-
guish the rodent and human peptides. These substitutions influence the
specificity of BACE1 cleavage. Human APP expressed in transgenic mice is
preferentially cleaved at residue 1, producing peptides 38–43 amino acids in
length. In contrast, endogenous mouse APP is preferentially cleaved by
BACE1 at 11, generating peptides of 28–33 residues. Peptides ending at
amino acid 42 are shown for comparison.
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Western Blotting—Mice of each genotype (NTg and 1874,
n 3–5; lines 85 and 1874 85, n 10–15) were harvested at
8 months of age for assessment of amyloid pathology and
APP/A biochemistry. One-half of the brain was immersed in
4% paraformaldehyde and used for histology as described
below. The remaining hemisphere was frozen on dry ice and
prepared as a 20% homogenate that was used forWestern blot-
ting, filter trap assay, and ELISA.
Frozen hemi-brain samples were sonicated in 5 volumes of
1PBS containing 5mMEDTAand 1 protease inhibitormix-
ture (Mammalian cell mix, Sigma). Homogenates were further
diluted 1:1 with additional PBS/EDTA/protease inhibitor and
centrifuged at high speed for 10 min, and the supernatant was
used for analysis. Approximately 50 g of protein homogenate
per sample (5 g for 22C11) was loaded onto 4–12% BisTris
Novex gels (Invitrogen) and electrophoresed at 175 V for 1.5–2
h in 1MES buffer (Invitrogen). Proteins were transferred for
1 h at 100 V to 0.45-mOptitran nitrocellulose (Schleicher and
Schuell, Keene, NH) in 1NuPAGE transfer buffer made with
10% methanol and 1% antioxidant solution (Invitrogen). Blots
were blocked in PBS containing 5% nonfat dry milk powder for
30–60 min at room temperature. After blocking, blots were
incubatedwith primary antibody for either 3 h at room temper-
ature or overnight at 4 °C. The following primary antibodies
and dilutions were used: 6E10 mouse anti-human A mono-
clonal (Signet Laboratories, Dedham, MA) 1:2000; rabbit anti-
rodentAPPpurified polyclonal antibody (AB5571P, Chemicon,
Temecula, CA) 1:2000; 22C11 mouse anti-APP N terminus
monoclonal, kind gift of Drs. Konrad Beyreuther and Andreas
Weidemann, 1:2000 (35); m/hSOD1 rabbit anti-SOD1 poly-
clonal, 1:4000 (36). After incubationwith primary antibody, the
blots were washed several times with PBS containing 0.1%
Tween 20, and then incubated with either goat anti-rabbit IgG
or goat anti-mouse IgG conjugated to horseradish peroxidase
(Jackson ImmunoResearch, West Grove, PA) diluted 1:2500 to
1:5000 in blocking solution. After washing several times in PBS
containing 0.1%Tween 20, blotswere developedwith enhanced
chemiluminescence reagent (ECL Plus, Amersham Bio-
sciences/GE Biosciences) and exposed to film. Intensity of
immunostaining was quantified from digitally scanned films
with ImageJ by first inverting to create a negative image and
then measuring the integrated density of each band. Back-
ground values calculated from a blank portion of the gel were
subtracted manually from each sample before assessing the
average signal intensity for the genotype.
A Immunoprecipitation—50l of the 20%PBShomogenate
described above was diluted 10-fold in radioimmunoprecipita-
tion assay buffer (0.2% SDS, 0.5% Nonidet P-40, 0.5% deoxy-
cholate, 5 mM EDTA, in 1 PBS) and boiled for 10 min. After
cooling, protease inhibitors were added, and the solution was
incubated overnight at 4 °C with 2 l of purified 4G8 (Signet
Laboratories). The antibody was recovered with protein A-aga-
rose beads (1 h at 4 °C), and nonspecific binding was removed
by several washes with additional radioimmunoprecipitation
assay buffer at 4 °C. The beads were heated to 95 °C for 5min in
2 Tricine-SDS sample buffer, and the entire reaction was
loaded onto 10–20% Tricine gels (Bio-Rad). Gels were pre-run
for 10 min prior to loading, and then run in 15-min voltage
steps of 25, 50, and 100, before running the gel to completion at
150 V. Protein was transferred to 0.45-mOptitran nitrocellu-
lose (Schleicher and Schuell) in 1 Tris-glycine/20% metha-
nol/0.1% SDS, after which the blot was boiled 5 min in 1 PBS
and blocked in 2% ECL Advance blocking reagent (Amersham
Biosciences/GE Biosciences)/1 TBS/0.1% Tween-20. Blots
were incubated overnight at room temperature with 4G8
diluted 1:10,000 in Advance block with 0.1% sodium azide.
After washing several times in blocking reagent, blots were
incubated for 2–3 h at room temperature with peroxidase-con-
jugated anti-mouse IgG diluted 1:20,000 in block. Blots were
washed thoroughly with TBS/0.1% Tween-20, developed with
ECL Advance (Amersham Biosciences/GE Biosciences), and
exposed to film 1 h after developing with ECL. To demon-
strate that 4G8 was capable of binding A11–42, several reac-
tions were run using 15 l of 20% homogenate spiked with
10–50 ng of synthetic human A11–42 (kindly provided by
Dr. David Teplow, UCLA).
A ELISA: Steady-state Levels (7–24 Weeks of Age)—Brain
tissue used for ELISA was harvested from female mice prior to
the onset of amyloid pathology (lines 1874, 85, and 1874 85:
7–10 weeks of age; line 1874 S-9: 9–24 weeks of age). Frozen
mouse hemi-brains (n 4–6 per genotype) were extracted by
sonication in 0.2% diethylamine (DEA)/50 mM NaCl at a con-
centration of 100mg/ml. After centrifugation at 100,000 g for
1 h at 4 °C, the supernatant was removed and saved as the DEA
extract. The pellet was then sonicated in 70% formic acid (FA)
diluted in water, using a volume equal to the original volume of
DEA. After centrifugation at 100,000  g for 1 h at 4 °C, the
supernatantwas removed and saved as the FAextract. TheDEA
extracts were neutralized by adding a 1/10 volume of 0.5 M
Tris-HCl, pH 6.8. The FA extracts were neutralized and pre-
pared for ELISA by diluting 1:20 in 1 M Tris-phosphate buffer,
pH 11. The samples were then assayed by sandwich ELISA as
described below.
A ELISA: Amyloid Solubility (8 Months of Age)—An aliquot
of PBS 20% homogenate generated for Western analysis
described above was subjected to a three-step sequential
extraction using PBS, 2% SDS, and 70% formic acid (NTg and
line 1874,n 4; lines 85 and 1874 85,n 8). At each step, the
sample was sonicated in appropriate buffer and centrifuged at
100,000  g for 30 min at 4 °C. The supernatant was removed
for analysis, and the pellet was sonicated in an equal volume of
the next solution in sequence. The 2% SDS extracts were
diluted at least 1:40 in EC buffer (0.02 M sodium phosphate
buffer, pH 7.0, 2 mM EDTA, 400 mM NaCl, 0.2% bovine serum
albumin, 0.05% CHAPS, 0.4% BlockAce (Dainippon Pharma-
ceuticals), 0.05% NaN3), prior to testing to bring the SDS con-
centration below 0.05%; the FA extracts were neutralizedwith 1
M Tris-phosphate buffer, pH 11, and then diluted with EC
buffer prior to testing.
Brain extracts were measured by sandwich ELISA as
described previously (37–39).HumanAwasmeasured in each
fraction using BAN50 for capture (epitope A1–16) and BA27
and BC05 for detection (A40 and A42, respectively). Total
A (mouse plus human) was measured in each fraction using
BNT77 for capture (epitope A 11–28) and BA27 and BC05 for
detection. AlthoughBNT77 recognizes bothmouse andhuman
Murine A Alters Solubility of Human Amyloid
AUGUST 3, 2007•VOLUME 282•NUMBER 31 JOURNAL OF BIOLOGICAL CHEMISTRY 22709
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on August 17, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
A 1-x and 11-x, it does not bind -secretase processed APP
(40), and measurements with BNT77 therefore do not include
p3. All values were calculated as picomoles per g based on the
initial weight of brain tissue.
Filter Trap Assay—An aliquot of 20% PBS protein homoge-
nate from each 8-month-old animal was partially solubilized by
the addition of SDS to a final concentration of 1%. Serial 1:1
dilutions were made with 1 PBS/1% SDS, and 90 l of each
dilution was then vacuum-filtered through a pre-wet 0.22-m
cellulose acetate membrane (OE66, Schleicher and Schuell,
Keene, NH). Eachwell was washed several times with PBS, after
which blots were blocked for an hour in 1TBS plus 5% nonfat
dry milk powder. Blots were then incubated at 4 °C overnight
with polyclonal anti-A peptide antibody (71–5800, Zymed
Laboratories) diluted 1:600 in blocking solution. After washing
the blots several times in 1 TBS/0.1% Tween 20, the mem-
brane was incubated for 1 hwith an IRDye 800-conjugated goat
anti-rabbit IgG secondary antibody (Rockland Immunochemi-
cals, Gilbertsville, PA) diluted 1:5000 in blocking solution. The
membranes were again washed three times with 1 TBS/0.1%
Tween 20, given a final rinse in 1 TBS, and then imaged with
an Odyssey fluorescence imager (LI-COR, Lincoln, NE). Stain-
ing intensity for eachwellwas quantified usingOdyssey analysis
software, from which the linear range of the dilution series was
determined and used for all genotype comparisons.
Histology—Brains from lines 1874, 85, and 1874  85 were
harvested for histological analysis at 4 months (n  3–4 per
genotype) and at 8 months (n  5–14 per genotype) of age.
Mice were euthanized by ether inhalation, and the brain was
removed for analysis. One half was used for biochemical anal-
ysis described above; the remaining hemisphere was used for
histology. After immersion in 4% paraformaldehyde/1 PBS
for 48 h at 4 °C, the fixed hemi-brains were transferred to PBS,
dehydrated in an alcohol series, treatedwith cedar wood oil and
methylsalicylate, and embedded in paraffin for sectioning.
Hirano Silver Stain—Silver impregnation histology was per-
formed on 10-m paraffin-embedded sections by Hirano’s
modification of the Bielschowsky method (41, 42). Briefly, sec-
tions were deparaffinized through xylene and alcohols into tap
water before being placed into fresh 20% silver nitrate solution
for 20min. After washing thoroughlywith distilledwater, slides
were immersed in 20% silver nitrate solution titrated with fresh
ammonium hydroxide. After 20 min, slides were washed with
ammoniawater before being individually developedwith 100l
FIGURE 2. Transgenic expression increases moAPP 3-fold without lower-
ing co-expressed human APP. Western blots compare mouse and human
APP expression in brain homogenates from each of the four genotypes; four
animals (2 male and 2 female) from each genotype are shown. Blots show
immunodetection of total full-length APP and APP-like protein 2 (top panel,
22C11); rodent-specific APP (second panel, roAPP); human-specific APP (third
panel, 6E10); and SOD1 (Cu/Zn superoxide dismutase 1) as an internal control
(bottom panel). The 62- and 98-kDamarkers in the upper two panelsmigrated
more slowly than expected based on the known size of APP andwere consis-
tently positioned lower on the BisTris gels run in MES buffer than in previous
studies using Tris-HCl gels in Tris-glycine-SDS buffer.
FIGURE 3. ELISA analysis confirms that transgenic expression of moAPP
increases pre-deposit steady-state A levels. A, brain homogenates from
each of the lines indicatedwere assayed at 2.5 (lines 1874, 85, and 1874 85)
or 6months of age (line 1874 S-9) for human-specific A40 (open bars) and
A42 (filled bars). As predicted, lines 85 and 1874  85 produce identical
levels of human peptide. B, measurement of total A (mouse plus human)
using the same samples assayed for humanA in panel A. Note that A levels
in line 1874 85 are roughly the sum of A levels in the separate lines. Data
are shown S.E. *, p 0.05 versus line 85. †, p 0.05 versus line 1874.
TABLE 1
ELISAmeasurement of steady-state A levels in 4-month-old mice
Values are in picomoles/g wet tissue weight (S.E.).
DEA FA
n
40 42 40 42
pmol/g
Human A-BAN50
capture
1874a 0.06 (0.035) 0.02 (0.018) 1.19 (0.103) 0.10 (0.103) 5
1874 S-9a 0.04 (0.037) 0.02 (0.008) 1.04 (0.147) 0.23 (0.196) 6
85 9.25 (1.19) 6.71 (1.06) 8.17 (0.56) 8.53 (0.92) 4
1874 85 8.85 (0.67) 6.22 (0.46) 8.62 (0.25) 7.86 (0.38) 4
Total A-BNT77
capture
1874 8.17 (0.33) 1.61 (0.049) 5.51 (0.35) 2.70 (0.25) 5
1874 S-9 7.23 (0.33) 3.98 (0.15) 5.60 (0.31) 5.61 (0.24) 6
85 17.49 (1.78) 9.81 (1.17) 10.90 (0.57) 10.23 (1.40) 4
1874 85 23.30 (1.24) 12.51 (0.28) 14.37 (0.79) 12.91 (0.87) 4
a The capture antibody for this assay (BAN50) is specific for human A. Values
obtained for 1874 and 1874 S-9 represent background binding.
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of developer (20 ml of 37% formaldehyde, 100 ml of distilled
water, 50 l of concentrated nitric acid, and 0.5 g of citric acid)
added to 50 ml of titrated silver nitrate solution. Slides were
then rinsed in tap water, fixed in 5% sodium thiosulfate, and
dehydrated through alcohols and xylene.
Campbell-Switzer Silver Stain—A detailed protocol for this
stain was kindly provided by Dr. Bob Switzer of NeuroScience
Associates.
Thioflavine-S Staining—Following deparaffinization of sec-
tions through xylene and alcohols, amyloid impregnation with
thioflavine-S was performed according to the Guntern modifi-
cation of the standard protocol. Slides were washed twice in
distilled water, then immersed for 5 min in a 0.25% potassium
permanganate solution, followed by 5 min in a 1% potassium
metabisulfate/1% oxalic acid solution. After this preparation,
slides were placed into a filtered aqueous 0.02% thioflavine-S
solution (Chroma-Gesellschaft, Schmid GmbH and Co., Kon-
gen, Germany) for 8min. Excess stainwas removed by two brief
rinses in 80% ethanol, then two in distilled water, after which
slides were finished in aqueous mounting medium for flores-
cence photomicrography.
A Immunohistochemistry—Prior to immunostaining, slides
were deparaffinized by oven heating followed by immersion in
xylene. After rehydration through
graded alcohols into tapwater, amy-
loid was partially denatured by
immersing sections in 80% formic
acid for 5min, followed by rinsing in
running tap water. Nonspecific
staining was blocked for 1 h with 3%
normal goat serum and 0.1% Tri-
ton-X 100 in TBS. Slides were then
placed into primary antibody (rab-
bit anti-human A peptide poly-
clonal antibody 71–5800 diluted
1:500, Zymed Laboratories; 6E10
mouse anti-human A monoclonal
antibody diluted 1:250, Signet Lab-
oratories; or rabbit anti-rodent APP
purified polyclonal antibody
AB5571P diluted 1:250, Chemicon)
in blocking solution and incubated
overnight at room temperature.
After washing with several changes
of TBS, slides were incubated either
with the Vectastain Elite anti-
mouse secondary system according
to the manufacturer’s directions (for
diaminobenzidine-developed anti-
A immunostaining, Vector Labora-
tories, Burlingame, CA) or withAlex-
afluor-conjugated goat anti-rabbit
(Alexa 568) and goat anti-mouse
(Alexa 488) secondary antibodies
diluted 1:100 in blocking solution
(for double immunofluorescence
immunostaining, Molecular Probes
c/o Invitrogen). Slides were again
rinsed several times in TBS and either mounted immediately in
fluorescence mounting medium (6E10/roAPP) or developed
with diaminobenzidine (Zymed Laboratories anti-A), coun-
terstained with hematoxylin, dehydrated and mounted.
Plaque Load Estimation—Amyloid burden was estimated
using non-biased stereology or image-based threshold analysis.
Three sagittal sections spaced at 200-m intervals were ana-
lyzed for each animal. Slides were analyzed by an investigator
blind to the genotype of the samples.
Non-biased Stereology—StereoInvestigator software (MBF
Biosciences, Colchester, VT) was used to estimate the surface
area covered by plaques stained with A immunohistochemis-
try (Zymed Laboratories, 71-5800 anti-A polyclonal) using an
area fraction fractionator grid (Cavalieri spacing: 500  500
m, grid spacing: 10 m, frame size: 85  110 m, 40 mag-
nification). Percent coverage within the cortex of each animal
was averaged from three sections to obtain a final estimate of
plaque burden.
ImageJ-based Threshold Analysis—Sections stained for A
immunohistochemistry or Campbell-Switzer silver were
scanned using an Epson 4990 flatbed scanner set for film at
2400 dpi. Images were brought into ImageJ and converted to an
8-bit grayscale. The cortex was outlined manually using a
FIGURE 4. Overexpression of mouse APP does not enhance senile plaque pathology in mice producing
human A. Amyloid staining by A immunohistochemistry (top row), Campbell-Switzer silver stain (second
row), and thioflavine-S (third row) produce qualitatively similar images in 8-month-old mice overexpressing
humanA (line 85) versus those overexpressing bothmouse and human peptide (line 1874 85). High power
(40) images of plaques stained by A immunohistochemistry (bottom row, left) and by Hirano silver stain
(bottom row, right) suggest that the structure of amyloid aggregates in both lines is also similar. By itself,
overexpression of mouse APP (line 1874) failed to produce amyloid plaques at any age examined.
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WacomGraphire tablet, the surrounding area was cleared, and
the automatic threshold within the remaining image was deter-
mined (but not applied to the image). The percent surface area
above threshold was then determined using the Analyze Parti-
cles command.
Vascular Amyloid Quantitation—Sections from 8-month-
old mice that had been stained for A immunohistochemistry
were viewed at 40 under standard brightfield conditions. All
amyloid deposits within onemicroscopic field of the dorsal cor-
tical surface running from the frontal to occipital poles were
examined. Blood vessels were identified by morphology with
hematoxylin counterstain; all vessels positive for Awereman-
ually counted by an investigator who was blind to the genotype
of the sample. Only parenchymal vessels were considered; amy-
loid-positive vessels in themeninges at the pial surfacewere not
counted. Three sections, spaced at 200-m intervals, were
averaged for each animal (line 85: n 9; line 1874 85 n 8).
Statistics—All data were analyzed for statistical significance
by ANOVA followed with Tukey post-test using SigmaStat
analysis software (Systat Software, Port Richmond, CA).
RESULTS
APP Expression and Steady-state A Levels Are Elevated Sev-
eralfold by Transgenic Expression of moAPP—Two lines of
transgenicmicewere used for these studies. The first line, here-
after referred to as line 85, co-expressed a chimeric mouse/
human APP 695 (human A sequence) harboring the Swedish
K594M/N595L mutation (using 695 numbering) alongside
human PS1 harboring the exon-9 deletion mutation (PS1dE9).
Each transgene is controlled by an independent mouse prion
promoter. The two transgenes are co-integrated and segregate
as a single locus, making all mice from this line transgenic for
both proteins. The second line, hereafter referred to as line
1874, expressed wild-type mouse APP 695 under the control of
the hamster prion promoter (30), which produces a similar pat-
tern of transgene expression as themouse prion promoter used
for line 85 (32). Interbreeding of the two lines generatedmice of
four genotypes (non-transgenic (NTg), 1874 (single trans-
genic), 85 (double transgenic), and 1874  85 (triple trans-
genic)) that were analyzed to determine the impact of mouse
A on the timing and extent of human A deposition.
Both lines 85 and 1874 overexpressed transgenic APP at lev-
els severalfold over the endogenous protein. Immunoblotting
for the full-length protein was used to quantify how well the
transgene expressed each line and to ensure that expression of
one APP transgene was not diminished by co-expression of the
second in 1874 85 triple transgenic (mo/huAPPswe/PS1dE9/
moAPPwt) offspring. Three separate antibodies were used for
this analysis: 22C11, which recognizes from both mouse and
human the N terminus of mature and unprocessed APP as well
as APP-like protein 2 (43); 6E10, which recognizes the N-ter-
minal region of humanA; and a rodent-specific APP antibody,
which recognizes the N-terminal region of mouse A (Fig. 2).
Quantitation with 22C11 and roAPP indicated that line 1874
expressed between 2.5- (2.46 0.05; roAPP) and 4-fold (3.98
0.36; 22C11) more APP than NTg. APP overexpression in line
85 appeared somewhat lower than in line 1874; blotting with
22C11 revealed 3-fold more APP than NTg (2.89  0.13).
Expression levels in the triple transgenic line 1874  85 were
roughly the sum of that in each parental line (7.28  0.27;
22C11). Most importantly, comparison of mo/huAPPswe
FIGURE 5.Quantitationof senile plaqueburden confirms that plaque for-
mation is not increased by the addition of extra mouse A. The panels
showscatterplotsof thepercent surfacearea coveredbyamyloidat 8months
of age within the cortex of individual mice for each genotype. Coverage was
assessed by two independent methods: non-biased stereology with Stereo-
Investigator software (A) orbydigital thresholdanalysiswith ImageJ (BandC).
Sections used for analysis were stained for amyloid with an anti-A antibody
(A and B) or by silver impregnation using the Campbell-Switzer Alzheimer’s
stain (C). The three analyses reached similar conclusions: overexpression of
mouse A does not change the extent of amyloid formation in the cortex of
animals depositing human A.
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expression in lines 85 and 1874 85, and of moAPPwt in lines
1874 and 1874 85, indicated that co-expression of the second
APP transgene did not diminish expression of the first. Levels of
mo/huAPPswemeasured by 6E10 immunoblotting were nearly
identical in the line 85 and 1874 85 brains (2.24 0.16 (line
85) versus 2.03  0.06 (line 1874  85), in arbitrary units;
ANOVA: F1,7  3.228, p  0.122). Likewise, expression of
mouse APPmeasured with roAPPwas similar in lines 1874 and
1874 85 (5.64 0.11 (line 85) versus 5.92 0.06 (line 1874
85), in arbitrary units, ANOVA for all four genotypes F3,12 
66.219, p  0.001, Tukey post-hoc for pairwise comparison of
85 versus 1874  85 p  0.900). These findings indicate that
there is no change in the expression of one APP transgene
caused by the introduction of a second.
We next assessed steady-state levels of A in the 1874, 85,
and 1874  85 mice. Brain tissue was harvested from young
mice prior to the formation of amyloid deposits. These analyses
also included mice derived from the mating of line 1874 line
S-9, which overexpresses human PS1 encoding the exon 9 dele-
tion. Both A40 and A42 levels were measured by ELISA
using two different capture antibodies to distinguish human
peptide from total A (mouse plus
human). The human-specific cap-
ture antibody BAN50 recognizes
only full-length human A1-x,
whereas the BNT77 capture anti-
body that detects both mouse and
human A recognizes full-length
A in addition to A11-x (but not
-secretase products 17-x). There-
fore, when referring to ELISA
results with BNT77, we designate
the peptides as x-40 and x-42. Con-
sistent with the immunoblot dem-
onstrating equal expression of
mo/huAPPswe, brain tissue from
line 85 and 1874  85 mice con-
tained nearly identical levels of
humanA peptide (Table 1 and Fig.
3; A40: 17.42  3.53 (line 85) ver-
sus 17.47  1.39 (line 1874  85)
pmol/g tissue, ANOVA for all four
genotypes: F3,15  139.75, p 
0.001, Tukey post-hoc for pairwise
comparison of 85 versus 1874  85
p 1.0; A42: 15.24 3.87 (line 85)
versus 14.08 1.17 (line 1874 85)
pmol/g tissue, Tukey post-hoc p 
0.808). Similarly, levels of total A
(mouse plus human) paralleled the
expression of total APP measured
by 22C11. Line 1874 mice produced
almost as much mouse Ax-40 as
line 85 mice produced of human
A1–40 (13.68  0.76 pmol/g of
tissue) butwithmuch lower levels of
Ax-42 (4.31 0.67 pmol/g). Intro-
duction of the FAD-variant PS1dE9
in mice expressing moAPP more than doubled production of
Ax-42 without impacting Ax-40 (line 1874  S-9, A40:
12.83  0.69; A42: 9.59  0.81 pmol/g), consistent with our
previouswork on this PS1 variant (11). The amount ofA in the
triple transgenic 1874  85 mice was roughly the sum of A
levels measured in each line separately (A40: 37.66  3.28,
A42: 25.41  2.24 pmol/g). Steady-state levels of A40 are
significantly higher in the triple transgenic 1874 85mice than
in their double transgenic line 85 siblings (ANOVA: F3,15 
98.94, p  0.001, Tukey post-hoc p  0.001); as are levels of
A42 (ANOVA: F3,15 66.47, p 0.001, Tukey post-hoc p
0.037). In sum, 1874 85 brain harbors significantlymore total
A peptide than does line 85 (48.42  4.76 (line 85) versus
63.08  2.25 (line 1874  85) pmol/g). Based on our previous
study of APP and APP/PS1 transgenic mice, these data predict
an earlier onset of amyloid deposition, with a greater plaque
burden at any given age in the triple transgenic mice compared
with their double transgenic siblings (11).
Plaque Burden Is Not Increased or Accelerated by Overpro-
duction of Mouse A—Line 1874 produces 2- to 4-fold more
APP than wild-type animals, which is in the range needed to
FIGURE6.Participationof rodentA inamyloidplaquesdoesnot increasewithoverexpressionofmouse
APP.Double immunostaining for human (top row, 6E10, and green) andmouse A (middle row, roAPP, and red)
reveals that human peptide is the dominant species depositing in 8-month-old mice overproducing APP. A
minimal core of rodent immunostaining is seen in most plaques; this signal does not increase even when
mouse APP/A levels are elevated severalfold (line 85 versus 1874 85). The top panels show immunostaining
for each genotype at low power; the bottom panels highlight immunostaining in plaques at higher magnifica-
tion (40).
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produce amyloid pathology in transgenic lines expressing the
mutant human protein (11). Despite high levels of transgene
expression, long term study of line 1874 found no evidence for
amyloid formation in mice up to 24 months of age (data not
shown). Similarly, the 1874  S-9 mice also failed to develop
amyloid deposits by 2 years of age (data not shown). These
findings suggest that either mouse A is incapable of initiating
amyloid deposits in vivo, or that there is too little A42 pro-
duced in these lines to aggregate within the 24-month mouse
lifespan.
Wenext addressedwhethermouseA could accelerate amy-
loid formation fromhumanA by crossingmice from line 1874
to line 85. Previous studies in line 85 indicated that amyloid
formation begins at about 5–6 months of age in this line. We
therefore chose two ages for analysis that bracketed this onset
to test whether addition of extra mouse A introduced in the
triple transgenic 1874 (moAPPwt)  85 (mo/huAPPswe/
huPS1dE9) offspring would alter the rate of human A deposi-
tion. The first set ofmicewas harvested at 4months of age, with
the expectation that raising the steady-state A level in the
triple transgenics would accelerate its aggregation into plaques.
Instead we found no sign of amyloid formation in any of the
mice examined at this age, regardless of genotype or gender
(data not shown). Despite carrying significantly more total A,
the 1874  85 mice formed cored-amyloid deposits no faster
than their line 85 siblings.
We next examined amyloid burden in 1874 85 offspring at
a time point after deposits were known to appear in line 85
animals. We found that, by 8 months of age, amyloid deposits
were apparent in brains fromboth the line 85 double transgenic
animals and their 1874  85 triple
transgenic siblings. Qualitatively,
there was little to distinguish
between genotypes: plaques were
found throughout the cortex and
hippocampus of most animals, with
no obvious difference in the relative
appearance of the deposits or the
surrounding tissue (Fig. 4). The dis-
tribution of plaques appeared simi-
lar in line 85 and 1874 85 sections
stained with silver or A immuno-
staining, and a fraction of the depos-
its in both genotypes bound Thio-
flavine-S. Non-biased stereology
supported this observation. Analy-
sis of the percent surface area cov-
ered by plaques in the cortex of A-
immunostained sections revealed
almost complete overlap of the two
genotypes (Fig. 5; line 85: 3.08% 
0.52; line 1874 85: 2.61% 0.56).
This conclusion was confirmed by a
second method of quantitation
using ImageJ (see “Experimental
Procedures”). Both silver and A
immunostained sections were ana-
lyzed by digital imaging; both
yielded the same outcome (Fig. 5; silver: 1.77% 0.17 (line 85)
versus 1.71%  0.19 (line 1874  85); A immunostaining:
1.74%  0.22 (line 85) versus 2.16%  0.40 (line 1874  85)).
Overproduction of mouse A did not alter the timing or the
extent of amyloid formation in mice producing human A.
Although we found that amyloid burden in the brains of
1874  85 mice did not change as a result of overproducing
mouse A, we wanted to know whether the relative amount of
mouse A co-deposited with human peptide would increase as
more mouse peptide was produced. We used double immuno-
fluorescence to label mouse (roAPP) and human (6E10)
APP/A in 8-month-old mice of each genotype (Fig. 6). The
predominant signal in the plaques of both 85 and 1874  85
mice is from the human peptide. Human immunostaining is
present within all plaques observed in both genotypes. Mouse
APP/A immunostaining is present within most plaques but
covers a muchmore restricted and focal area within the core of
the deposits. Occasional plaques staining with the human anti-
body can be found that do not co-label formouse peptide; these
are predominantly either diffuse or very small deposits. The
most notable finding of this experiment was the similarity of
parenchymal amyloid staining in the 85 and 1874  85 mice.
Although the triple transgenic mice produced much more
mouse peptide than their double transgenic siblings, there was
no change in the extent of immunostaining for mouse APP/A
in their plaques.
Vascular Amyloid Is Increased by Overexpression of Mouse
A—Careful examination of A-immunostained sections
revealed that vascular amyloid deposits were more common in
the 1874  85 mice than in their double transgenic siblings.
FIGURE 7. Overproduction of mouse A increases deposition of human A in cortical blood vessels.
A–D, immunostaining for A is more often found within the vasculature of 8-month-old triple transgenic
187485mice than in their double transgenic siblings. E, quantitationof amyloid-positivebloodvessels in the
cortex of A-immunostained sections reveals a significant increase in cerebral amyloid angiopathy in 1874
85mice comparedwith their line 85 siblings. F–I, amyloid deposits appear in close proximity to, but usually not
within cortical blood vessels (indicated by arrowheads) of line 85 animals. J and K, like the parenchymal depos-
its, vascular amyloid in line187485mice containsbothhuman (E; 6E10) andmouse (F; roAPP)APP/A. Panels
A–D and F–I show representative images from three animals for eachgenotype; all imageswere taken at 100.
*, p 0.005 versus line 85.
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Although both genotypes displayed extensive accumulation in
blood vessels at the pial surface, A immunostainingwas rare in
vessels within the cortex for line 85. Small amyloid deposits
were often seen within close proximity to blood vessels, but the
vessel wall was usually clean. By comparison, the appearance of
vascular amyloid reactive with human-specific 6E10 antibody
was much more common in the tri-
ple transgenics (Fig. 7). Here, the
entire circumference of some ves-
sels stained for A. However, amy-
loid-positive vessels still comprised
only a small fraction of the total vas-
culature in each section. Nonethe-
less, the phenotype was consistent
enough to allow a blinded investiga-
tor to correctly identify the geno-
type of tissues samples from 15 out
of 19 animals based solely on the
presence or absence of vascular
deposits. This qualitative assess-
ment was confirmed by quantita-
tion: manual counting of amyloid-
positive vessels within the cortex
revealed the 1874 85mice to have
7.8-fold more A-positive vessels
per section than their line 85 sib-
lings (85: 2.53 0.72 amyloid-posi-
tive vessels per section; 19.67 
4.89; ANOVA: F1,15  13.54, p 
0.005).
Mouse A Increases the Detergent
Solubility of Human Peptide Ag-
gregates—To extend our histologi-
cal data, we used filter-trap and
ELISA measurements to assess the
solubility and composition of accu-
mulated A in mice of the various
genotypes. The filter-trap assay uses
a cellulose acetate filter to trap pro-
tein aggregates larger than the pore
size within themembrane for detec-
tion by immunoblotting (Fig. 8).
Serial dilutions are made in 1% SDS,
which is harsh enough to partially
solubilize even human AD amyloid
(44). Unexpectedly, we found that
protein extracts from the 1874 85
mice contained substantially less
trapped A than extracts from line
FIGURE 8.Overexpression ofmouse APP increases the solubility of human A aggregates. A, representative
example of a filter-trap assay for aggregated A in serial dilutions of brain homogenates from 8-month-old mice.
Each row represents a separate mouse. Lacking aggregated peptide, NTg and 1874 homogenates showed no
immunostainingforA. Both lines85and187485havesignificant levelsofaggregatedA, however, lesspeptide
was retained from the 1%SDShomogenates inmice overexpressingmouse andhumanAPP than in those overex-
pressing only the human protein. B, average intensity of immunostaining within the linear range of the filter-trap
dilution series for each genotype reveals a dramatic reduction of aggregated A in the SDS extracts of mice over-
expressingmouseandhumanAPP(line187485)comparedwithanimalsoverexpressingonly thehumanprotein
(line 85).C, Western blot of protein homogenate (lanes 1–6) and extracted filter trapwells (lanes 7–18) probedwith
human-specific antibody 6E10. Consistent with the greater intensity of staining on the serial dilution filter trap
shown in A, the extracted wells from line 85 mice contained more aggregated A than those from 1874  85.
D, filter-trapquantitationused togenerate thegenotype averages shown inC areplotted as individual data points.
E, separation of genders within each genotype reveals that males carried the lowest, and females the highest,
individual amyloid burdens within each group. This is consistent with previous work describing greater amyloid
loads in femalemice of several other APP transgenic lines (54, 55). *, p 0.005 versus line 85.
TABLE 2
ELISAmeasurement of human and total (mouse plus human) A in brain tissue from 8-month-old mice
Values are in picomoles/g wet tissue weight (S.E.).
PBS SDS FA n40 42 40 42 40 42
pmol/g
Human A-BAN50 capture
85 2.98 (0.33) 4.13 (0.41) 159.5 (23.4) 710.6 (106.0) 172.2 (31.3) 697.6 (107.9) 8
1874 85 2.15 (0.077) 5.20 (0.34) 61.9 (5.61) 1047 (112.9) 65.0 (10.1) 685.8 (109.5) 8
Total A-BNT77 capture
85 3.56 (0.35) 2.58 (0.25) 192.9 (30.6) 676.6 (102.1) 118.4 (39.26) 721.8 (107.8) 8
1874 85 3.19 (0.10) 3.79 (0.17) 66.8 (8.61) 1306 (148.6) 81.7 (11.82) 808.7 (132.1) 8
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85. Quantitation of staining intensity within the linear range of
the dilution series revealed that, on average, the triple trans-
genic animals harbored less than half the amount of filter-
trapped A than their double transgenic counterparts (22.10
2.87 (line 85) versus 10.80  1.20 (line 1874  85) in arbitrary
units, ANOVA for all four genotypes: F3,24 14.60, p 0.001,
Tukey post-hoc for pairwise comparison of 85 versus 1874 85
p 0.003). This outcome appeared to contradict our histolog-
ical analyses showing similar amyloid burden in the brains of
the two models. However, because the homogenates were pre-
pared in 1% SDS, we thought it possible that the amyloid depos-
ited in the 1874 85 mice might be more soluble in SDS than
the amyloid accumulating in the line 85 mice.
By contrast to the filter-trap assay, ELISA measurements of
A showed that the levels of total human A in 8-month-old
1874  85 mice were similar to that of age-matched line 85
mice (Table 2). However, these ELISA experiments used a
three-step sequential extraction and sedimentation protocol.
Tissue homogenates were first extracted with PBS, followed by
2% SDS, and finally by 70% formic acid, revealing interesting
differences in amyloid solubility at each step. As a fraction of
the total humanA in each group,more of the accumulatedA
was soluble in SDS in line 1874 85 mice than in line 85 mice,
leaving less A to recover in the final formic acid extraction
(Table 2 andFig. 9; SDS: 50.1 1.4% (line 85) versus 60.2 2.2%
(line 1874 85), ANOVA for all four genotypes: F3,20 78.85,
p  0.001, Tukey post-hoc for pairwise comparison of line 85
versus 1874  85 p  0.017; FA: 49.5  1.5% (line 85) versus
39.4  2.18% (line 1874  85), ANOVA: F3,20  45.53, p 
0.001, Tukey post-hoc p  0.063, however direct comparison
by Student’s t test yielded p 0.001). Underlying this trendwas
a 47% increase in the amount of SDS-soluble human A42
(710.6 pmol/g (line 85) versus 1047.3 pmol/g (line 1874  85);
ANOVA: F3,20  22.68, p  0.001, Tukey post-hoc p  0.075,
with direct comparison by Student’s t test, p  0.047) along
with a 62% decrease in the amount of FA-soluble human A40
(172.2 pmol/g (line 85) versus 65.0 pmol/g (line 1874  85);
ANOVA: F3,20 13.11, p 0.001, Tukey post-hoc p 0.005).
The addition of excess mouse APP significantly decreased
the accumulation of human A40 in all three fractions (PBS:
28% decrease; 2.98 pmol/g (line 85) versus 2.15 pmol/g (line
1874 85), ANOVA for all four genotypes: F3,20 38.19, p
0.001; Tukey post-hoc for pairwise comparison of 85 versus
1874 85 p 0.041; SDS: 61% decrease, 159.5 pmol/g (line 85)
versus 61.9 pmol/g (line 1874 85), ANOVA:F3,20 21.15, p
0.001, Tukey post-hoc p  0.001; FA: 62% decrease described
above) causing a 61% overall decrease in total A40 (334.7
pmol/g (line 85) versus 129.1 pmol/g (line 1874 85), ANOVA:
F3,20  16.93, p  0.001, Tukey post-hoc p  0.002). By con-
trast, the amount of human A42 did not differ significantly
between the two groups.
In contrast to the marked decrease in A 40, the amount of
total A42 (mouse plus human) was substantially higher in the
8-month-old 1874  85 mice than in their double transgenic
siblings (Fig. 8; 1400.9 pmol/g (line 85) versus 2118.3 pmol/g
(line 1874 85), ANOVA for all four genotypes: F3,20 19.55,
p 0.001; Tukey post-hoc for pairwise comparison of 85 versus
1874 85 p 0.082; with direct comparison by Student’s t test,
p 0.05). The increase in A42 was composed primarily from
a 93%gain in SDS-soluble peptide (676.6 pmol/g (line 85) versus
1305.8 pmol/g (line 1874  85), ANOVA: F3,20  24.97, p 
0.001, Tukey post-hoc p  0.003). The higher level of total
A42 in the 1874  85 mice suggests a substantial accumula-
tion of mouse peptide.
N-terminally Truncated Mouse A Is Not a Major Compo-
nent of Amyloid Formed in Transgenic Mice—Prior studies of
the interaction between BACE1 and APP suggested that the
endogenous protease preferentially cleaves rodent APP at the
11 site within A (12, 22–25). This cleavage generates pre-
dominantly N-terminally truncated A 11-x from moAPP. To
determinewhether the alterations in amyloid solubility and dis-
tribution in the triple transgenic mice correlated with co-dep-
osition of mouse A11-x, we immunoprecipitated A from
brain homogenates of both line 85 and 1874 85mice using an
antibody that would detect both full-length and 11-x peptides
(4G8). To our surprise, we found no evidence of A11-40/42 in
the brains of triple transgenic mice (Fig. 10). In contrast to the
intense signal from full-length 1–40/42 peptides, A11–40/42
was undetectable in the immunoprecipitates. Control experi-
ments clearly demonstrated that 4G8 was capable of immuno-
precipitating and detecting synthetic A11-x added to homo-
genates prepared from line 85 mice with high amyloid burden
(Fig 10). Moreover, these immunoprecipitations were highly
sensitive: as little as 10 ng of exogenous A11–42 could be
recovered and detected from 1 mg of mouse brain protein by
this method. Thus, we conclude that mouse A11–42 is not a
major component of the amyloid deposited in our triple trans-
genic animals and that factors other than peptide length must
influence the solubility and localization of humanA in the line
1874 85 animals.
FIGURE 9. ELISA analysis of aggregated A in 8-month-old transgenic mice. Brain homogenates were sequentially extracted with PBS, 2% SDS, and FA
before each fraction was assayed for human-specific and total (mouse plus human) A40 and A42. Data from this experiment are tabulated in Table 2.
A, accumulation of human A40 was significantly reduced in all three fractions by the expression of exogenous mouse APP. Conversely, human A42 levels
increased in the SDS-fraction of triple transgenic mice. B, total A levels (mouse plus human) mirror the differences found in human A. SDS- and FA-soluble
A40 was significantly lower, whereas SDS-soluble A42 was significantly higher, in line 1874  85 than in line 85. C, overexpression of mouse APP/A
significantly decreased the accumulation of both human and total (mouse plus human) A40 summed across all three fractions. The accumulated sum of
human A42 is not significantly changed; however, the amount of total (mouse plus human) A42 is substantially higher in the 1874 85 mice, suggesting
that mouse A42 may account for the extra peptide. D, the two genotypes harbor statistically indistinguishable amounts of human A (40 plus 42) in each
fraction andaccumulate nearly identical amounts of total humanpeptide (PBSplus SDSplus FA). E, totalmouseplus humanA (40plus 42) differs between the
two genotypes only in the SDS-soluble fraction. Despite this increase in SDS-soluble peptide, the overall amount of total A (PBS plus SDS plus FA) in line
1874 85 is statistically indistinguishable from line 85. F, although the absolute amount of human A extracted into each fraction is identical in each line, the
relative levels differ substantially. A greater fraction of the accumulated A is soluble in SDS in line 1874 85 than in line 85. The 1874 85 animals show an
attendant decrease in the percentage of FA-soluble peptide. G, similar to the case for human A, a greater fraction of total mouse plus human A is soluble in
SDS, and correspondingly less in FA, in the 1874 85 animals. Data are shown S.E. *, p 0.05; **, p 0.01; and ***, p 0.005 versus line 85 by ANOVA/Tukey
post-hoc; †, p 0.05 versus line 85 by Student’s t test (but not by ANOVA).
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DISCUSSION
We set out to test the amyloidogenic potential of mouse A
produced in its normal environment within the mouse brain
and to understand how the presence of mouse A influences
the deposition of human A in transgenic models for Alzhei-
mer disease. Previous studies have shown that full-length
mouse A aggregates as readily as the human peptide in vitro
and that the two species form co-polymers that are indistin-
guishable from pure human fibrils (16, 17). Our findings indi-
cate a more complicated picture when these processes occur
in vivo. We show that mouse A on its own does not promote
the formation of mature senile plaques as aggressively as the
human peptide. We further show that mouse A does not
enhance the rate or severity of amyloid formed from human
A. Instead, the presence of excess mouse peptide had more
subtle effects on human A aggregation. The added mouse A
altered the detergent solubility of the human peptides and
shifted the A40:42 ratio of the aggregated human peptide;
humanA40 levels in the triple transgenic 1874 85micewere
50% lower than that of their age-matched line 85 siblings.
Excess mouse A also increased the relative burden of amyloid
deposited around cortical blood vessels. Overall, we conclude
that the addition of excess mouse APP/A has multiple effects
on the solubility, location, and composition of the amyloid
deposited in mice producing human A.
By itself, we found that overexpression of mouse A did not
lead to amyloid formation in moAPP transgenic mice. The lack
of deposition could be due to inadequate production of the
mouse peptide in our moAPP transgenic line. Transgenic
mouse APP was expressed at levels 3- to 4-fold that of endoge-
nous APP, but we had not included mutations that could have
augmented overall Aproduction.However, increasing the rel-
ative production of A42 by co-expressing PS1dE9 with the
mouse APP transgene also failed to produce cored-amyloid
deposits. Perhaps themost telling indicator of theminimal abil-
ity of mouse A to induce deposition was its lack of effect on
senile plaque formation inmice overproducing bothmouse and
human peptides. Despite its inability to influence the rate or
extent of amyloid formation in the moAPP APPswe/PS1dE9
triple transgenic animals, ELISAmeasurements of total A lev-
els suggest that mouse A was indeed accumulating alongside
the human peptide. Although the levels of human A were
nearly identical, 8-month-old triple transgenic animals har-
bored 30% more total A (mouse plus human) than their age-
matched APPswe/PS1dE9 siblings. The increase in total accu-
mulated A after the onset of amyloid deposition is roughly
equivalent to the steady-state overproduction of A in pre-
deposit triple transgenic mice. Thus, mouse A accumulation
in these animals is equal to its overproduction, but the accumu-
lation occurs without changing the rate or extent of amyloid
burden. Intriguingly, the extra A in the triple transgenic mice
is composed almost entirely of SDS-soluble material.
The presence of exogenous mouse A unexpectedly influ-
enced the solubility of human A accumulated in the brains of
moAPP  APPswe/PS1dE9 mice. This effect suggests a close
physical interaction between the two peptides. Previous studies
comparing amyloid formed in several transgenicmousemodels to
that from human AD patients had shown that plaques formed in
mice from the human peptide were more soluble in detergents
thanamyloid formed in thehumanbrain (45, 46).Ourdata suggest
that the higher solubility of amyloid formed in transgenic mice is
due in large part to the presence of mouse peptide rather than
differences in post-translational modification or local microenvi-
ronment. Three amino acids substitutions at positions 5, 10, and
13 may underlie this effect of mouse A. In particular, the His to
Arg substitution at position 13 disrupts ametal binding site in the
mouse peptide (18–20, 47),which could influence the structure of
the resulting mouse-human co-aggregates.
One of the more striking outcomes of co-expressing trans-
genic mouse APP with the mutant human protein was a dra-
matic increase in the appearance of vascular amyloid. A similar
shift fromparenchymal to vascular A deposition has also been
noted in several studies that have experimentally manipulated
the ratio of A40:42. However, depending on the mouse model
studied, both elevated and reduced A40:42 have been associ-
ated with increased cerebral amyloid angiopathy. Experimental
manipulations such as co-expressing human apoE4 with APP-
swe (48), or introducing the E693Q Dutch mutation into APP
transgenic mice (49), both elevated the ratio of A40:42 and
caused redistribution of amyloid deposits from the parenchyma
to the vasculature. Conversely, several experiments designed to
specifically lower the production ofA40 relative toA42, such
as co-expressingmutant PS1withAPP (50, 51) or expressing an
A42-exclusive transgene (52), are also reported to increase
cerebral amyloid angiopathy in transgenic mice. Our current
results are most consistent with the hypothesis that lowering
A40:42 increases the appearance of vascular amyloid. The triple
transgenic animals accumulated considerably more Ax-42 (and
considerably less Ax-40) than their double transgenic siblings
anddeveloped greater vascular pathology.Whether these two fac-
tors were causally related is unclear; it is most likely that the
A40:42 ratio is one of several factors that contributed to the
increased amyloid angiopathy in our line 1874 85mice.
Despite showing a significant effect on the solubility, compo-
sition, and location of human-amyloid, the distribution of the
accumulatedmouseA is unclear. Immunohistochemical anal-
yses demonstrated that some mouse A co-deposits with
FIGURE10.N-terminally truncatedmouseA isnotamajor componentof
amyloid aggregates. A, immunoprecipitation of A from brain homoge-
nates of 85 and 1874 85 mice demonstrates the abundance of full-length
A, but fails to detect any sign of N-terminally truncated mouse A 11-x.
Peptide was immunoprecipitated and detected with purified 4G8, which
binds a mid-region epitope common to both mouse and human A. 5 ng of
synthetic human A11–42 was run alongside the IP samples as a positive
control. B, immunoprecipitation of synthetic A11–42 spiked intoNTgor line
85 brain homogenates provides proof that 4G8 is capable of immunoprecipi-
tating theN-terminally truncated peptidewhenpresent. 50 ngof addedpep-
tide is shownhere, however, as little as 10ngof exogenousA11–42couldbe
recovered by immunoprecipitation under conditions identical to those
shown in panel A.
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human peptide in cored senile plaques. In addition, the triple
transgenic animals have considerably more amyloid in and
around cortical blood vessels. The worsening of vascular amy-
loid is consistent with the overall increase in total A levels in
the triple transgenic mice. However, vascular deposits in these
animals were reactive with both human-specific and rodent A
antibodies, and thus we cannot conclude that mouse A ini-
tiates this pathology or concentrates in this location. That the
majority of extra A (presumably mouse A) harbored in the
triple transgenics is soluble in SDS couldmean that this peptide
accumulates as diffuse amyloid. Mouse A may also be accu-
mulating in oligomeric structures that could be difficult to
detect histologically yet release substantial amounts of peptide
into detergent extracts.
Onemotivation behind this studywas to resolve a question that
arose regarding our recent study ofmice that expressmutantAPP
via an inducible promoter (53). Induction of mutant APP expres-
sion for 6 months resulted in robust amyloid pathology that,
although arrested by turning off the transgene, was not signifi-
cantly diminished following long periods of suppression. One
issuewe couldnot resolve in these studieswaswhethermouseA,
which was not regulated by the transgene, could provide a source
of peptide that would have maintained an equilibrium favoring
amyloid stability. The experiments we present here suggest that
this was likely not the case: mouse A, even when present in
excess, did not appear to promote senile plaque formation on its
own or enhance the deposition of human A in these structures.
Instead, we find that mouse Awould decrease stability of aggre-
gates formedbyco-depositionofbothpeptides.Thesedatamake it
unlikely that the presence of small amounts of endogenousmouse
Awould have the ability to sustain amyloid in our inducibleAPP
mice.Wethereforeconclude that thepersistenceof amyloid inour
APP-inducible mice is due to inherent stability of the human
amyloid.
Taken together, our studies demonstrate thatmouseA pro-
duced at 3- to 4-fold wild-type levels does not drive amyloid
formation in vivo nor does it accelerate the deposition of
human A in mice overproducing both peptides. However,
mouse A does accumulate with the human peptide, where it
increases the appearance of vascular deposits and alters the
overall solubility of resulting amyloid. These effects appear to
be mediated by full-length mouse A 1–40/42; A 11–40/42,
the predominant BACE product described in vitro, does not
accumulate to significant levels in vivo. That the solubility and
location of humanA aggregates can be influenced by the pres-
ence of mouse peptide suggests that a better understanding of
the effects of peptide sequence and species-specific processing
may provide new insight into disease mechanisms.
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